Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
Patients with heterozygous familial hypercholesterolaemia (HeFH), if untreated or undertreated, are characterised by lifelong exposure to elevated low density lipoprotein cholesterol (LDLc) levels, associated with a markedly increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent surveys, however...